Integrating AI tools into drug discovery introduces a mix of opportunities and challenges for startups and large pharmaceutical companies. These challenges often center on intellectual property (IP) risks, licensing...more
1/15/2025
/ Acquisitions ,
Artificial Intelligence ,
Documentation ,
Due Diligence ,
Innovation ,
Intellectual Property Protection ,
IP License ,
Life Sciences ,
Mergers ,
Patents ,
Pharmaceutical Industry ,
Risk Management ,
Startups
AI is poised to revolutionize drug discovery, but uncertainty in developing protectable IP in this emerging field creates a host of potential risks for companies innovating in this space. Further complicating things: not all...more
The scientific benefits and legal risks of AI-driven drug discovery are consequential. But recent IP law decisions allude to a general concept that IP rights will not be awarded if AI completely or significantly replaces...more
AI is shaving years off the drug-discovery process. But it’s not just leaving other research modalities in the dust—the law itself is struggling to keep up, especially when it comes to patenting AI-aided drug discovery....more
6/14/2024
/ Artificial Intelligence ,
Inventors ,
Life Sciences ,
Machine Learning ,
Patents ,
Pharmaceutical Industry ,
Research and Development ,
Risk Assessment ,
Risk Management ,
Startups ,
Strategic Planning ,
USPTO